# MXI1

## Overview
MXI1 is a gene that encodes the protein MAX interactor 1, a transcriptional repressor involved in regulating cell proliferation and differentiation. The MXI1 protein is a member of the Mad(Mxi1) family and is characterized by a basic helix-loop-helix leucine zipper (bHLH-Zip) domain, which facilitates its interaction with the MAX protein. This interaction forms heterodimers that compete with Myc-Max complexes for binding to E-box sequences in gene promoters, thereby repressing Myc target genes and contributing to growth arrest and terminal differentiation in normal tissues (Zervos1993Mxi1; SchreiberAgus1998Repression). MXI1's role as a tumor suppressor is underscored by its frequent mutation or deletion in various cancers, highlighting its importance in preventing excessive cell growth and tumorigenesis (Ko2011Mxi1). The protein's activity is modulated by interactions with other cellular components, including transcriptional repressors and ubiquitin ligases, which influence its stability and function in different cellular contexts (Huang2020UBE2O; Lee1999Mxi1).

## Structure
The MXI1 protein is characterized by a basic helix-loop-helix leucine zipper (bHLH-Zip) domain, which is crucial for its interaction with the MAX protein. This domain spans amino acids 32-112 and is similar to those found in Myc family proteins, allowing MXI1 to bind to Myc-Max recognition sites (Zervos1993Mxi1). The bHLH-Zip region in MXI1 shares significant sequence similarity with the Mad protein, particularly in the basic region and helix 1 (Zervos1993Mxi1). MXI1 also contains an acidic residue (Glu-87) in the leucine zipper, which may interact with Max's histidine (Zervos1993Mxi1).

MXI1 lacks a classical nuclear localization signal, but certain arginine and lysine residues might form a bipartite localization signal (Zervos1993Mxi1). The protein does not associate with itself but shows weak interactions with c-Myc and n-Myc under specific conditions, indicating a specific interaction with Max (Zervos1993Mxi1).

MXI1 has multiple isoforms, including Mxi1-SRa and Mxi1-SRb, which differ in their amino termini. Mxi1-SRa has a 103 amino acid extension at the amino terminal, including a Sin3 interacting domain (SID) and a proline-rich domain, enhancing its transcriptional repression potential (DugastDarzacq2004Mxi1SRα:). Mxi1-SRb has a 36 amino acid extension, also encoding a SID, crucial for repression and growth suppression activities (DugastDarzacq2004Mxi1SRα:).

## Function
The MXI1 gene encodes a protein that functions as a transcriptional repressor, primarily involved in regulating cell proliferation and differentiation. MXI1 is part of the Mad(Mxi1) family and acts by antagonizing the Myc family of proteins, which are key regulators of cellular growth and oncogenesis. MXI1 achieves this by forming heterodimers with the Max protein, thereby competing with Myc-Max heterodimers for binding to E-box sequences in gene promoters. This competition results in the repression of Myc target genes, contributing to the maintenance of a growth-arrested, terminally differentiated state in normal tissues (Lee1999Mxi1; SchreiberAgus1998Repression).

MXI1 is active in the nucleus, where it recruits transcriptional repressors such as mSin3 and histone deacetylases, facilitating chromatin remodeling and gene repression. This activity is crucial during terminal differentiation, where MXI1 levels increase as c-Myc levels decrease, leading to reduced cell proliferation (Lee1999Mxi1). The protein also plays a role in regulating the c-myc promoter, specifically targeting the P2 promoter to repress its activity, which is essential for controlling cell growth and proliferation (Lee1999Mxi1).

MXI1's function as a tumor suppressor is underscored by its location in a genomic region often mutated or deleted in cancers, highlighting its role in preventing excessive cell growth and potential tumorigenesis (Ko2011Mxi1).

## Clinical Significance
The MXI1 gene is implicated in various cancers due to its role as a tumor suppressor. In prostate cancer, MXI1 is located in a chromosomal region frequently altered in tumors, and its loss is associated with increased cell proliferation and tumorigenesis. Mice deficient in MXI1 exhibit prostate hyperplasia, supporting its role in suppressing prostate cancer development (Taj2001Mxi1). In lung cancer, MXI1 expression is significantly downregulated, and its low levels are linked to poor patient prognosis. The interaction between MXI1 and the ubiquitin ligase β-Trcp, which promotes MXI1 degradation, suggests that its downregulation contributes to lung cancer progression (Lei2022Mxi1; Huang2018S6K1).

In haematological malignancies, mutations in MXI1 have been identified, particularly in acute lymphoblastic leukemia, where they are associated with poorer clinical outcomes (Guo2007Expression). In glioblastoma, MXI1 is part of a chromosomal region often deleted, and its reintroduction in deficient cells results in decreased growth, indicating its tumor-suppressive function (Cascón2012MAX). Additionally, MXI1 is overexpressed in clear cell renal cancers, where it contributes to tumorigenesis in the absence of functional pVHL, highlighting its complex role in cancer biology (Tsao2008Inhibition).

## Interactions
MXI1 (MAX interactor 1) is a protein that interacts specifically with the MAX protein to form heterodimers. These MXI1-MAX complexes bind to Myc-Max recognition sites on DNA, but unlike Myc-Max heterodimers, they do not activate transcription. Instead, they act as transcriptional repressors by occupying these sites and preventing Myc-induced transactivation (Zervos1993Mxi1; Lahoz1994Suppression). MXI1 interacts strongly with Max and weakly with c-Myc, but not with other related proteins, as confirmed by immunoprecipitation and gel retardation experiments (Zervos1993Mxi1).

MXI1 is part of the Mad(Mxi1) family of proteins, which includes MAD1, and these proteins also form heterodimers with Max. This interaction is crucial during cell growth arrest and differentiation, where MXI1/MAX complexes replace MYC/MAX complexes, leading to transcriptional repression (SchreiberAgus1998Repression). MXI1 contains a basic helix-loop-helix leucine zipper (bHLH-Zip) motif, similar to Myc family proteins, facilitating its interaction with Max through favorable ionic interactions between their leucine zippers (Zervos1993Mxi1).

In the context of lung cancer, MXI1 is targeted for ubiquitination and degradation by the E3 ubiquitin ligase UBE2O, which promotes cancer progression and radioresistance. This degradation is facilitated by the phosphorylation of MXI1 by S6K1, which enhances its interaction with the β-Trcp ubiquitin ligase (Huang2020UBE2O; Huang2018S6K1).


## References


[1. (Zervos1993Mxi1) Antonis S. Zervos, Jenő Gyuris, and Roger Brent. Mxi1, a protein that specifically interacts with max to bind myc-max recognition sites. Cell, 72(2):223–232, January 1993. URL: http://dx.doi.org/10.1016/0092-8674(93)90662-a, doi:10.1016/0092-8674(93)90662-a. This article has 590 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/0092-8674(93)90662-a)

[2. (Taj2001Mxi1) Mary M. Taj, Rana J. Tawil, Lars D. Engstrom, Zhi Zeng, Clara Hwang, Martin G. Sanda, and Daniel S. Wechsler. Mxi1, a myc antagonist, suppresses proliferation of du145 human prostate cells. The Prostate, 47(3):194–204, May 2001. URL: http://dx.doi.org/10.1002/pros.1063, doi:10.1002/pros.1063. This article has 34 citations.](https://doi.org/10.1002/pros.1063)

[3. (DugastDarzacq2004Mxi1SRα:) Claire Dugast-Darzacq, Melinda Pirity, Jennifer K Blanck, Alexis Scherl, and Nicole Schreiber-Agus. Mxi1-srα: a novel mxi1 isoform with enhanced transcriptional repression potential. Oncogene, 23(55):8887–8899, October 2004. URL: http://dx.doi.org/10.1038/sj.onc.1208107, doi:10.1038/sj.onc.1208107. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1208107)

[4. (Lahoz1994Suppression) E G Lahoz, L Xu, N Schreiber-Agus, and R A DePinho. Suppression of myc, but not e1a, transformation activity by max-associated proteins, mad and mxi1. Proceedings of the National Academy of Sciences, 91(12):5503–5507, June 1994. URL: http://dx.doi.org/10.1073/pnas.91.12.5503, doi:10.1073/pnas.91.12.5503. This article has 87 citations.](https://doi.org/10.1073/pnas.91.12.5503)

[5. (Ko2011Mxi1) Je Yeong Ko, Kyung Hyun Yoo, Han-Woong Lee, and Jong Hoon Park. Mxi1 regulates cell proliferation through insulin-like growth factor binding protein-3. Biochemical and Biophysical Research Communications, 415(1):36–41, November 2011. URL: http://dx.doi.org/10.1016/j.bbrc.2011.10.005, doi:10.1016/j.bbrc.2011.10.005. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2011.10.005)

[6. (SchreiberAgus1998Repression) Nicole Schreiber-Agus and Ronald A. DePinho. Repression by the mad(mxi1)-sin3 complex. BioEssays, 20(10):808–818, December 1998. URL: http://dx.doi.org/10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U, doi:10.1002/(sici)1521-1878(199810)20:10<808::aid-bies6>3.0.co;2-u. This article has 145 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/(SICI)1521-1878(199810)20:10)

[7. (Guo2007Expression) Xiao-Ling Guo, Ling Pan, Xue-Jun Zhang, Xiao-Hui Suo, Zhi-Yun Niu, Jing-Yu Zhang, Fuxu Wang, Zuo-Ren Dong, Wanming Da, and Ruzo Ohno. Expression and mutation analysis of genes that encode the myc antagonists mad1, mxi1 and rox in acute leukaemia. Leukemia &amp; Lymphoma, 48(6):1200–1207, January 2007. URL: http://dx.doi.org/10.1080/10428190701342018, doi:10.1080/10428190701342018. This article has 12 citations.](https://doi.org/10.1080/10428190701342018)

[8. (Huang2020UBE2O) Yumei Huang, Xijie Yang, Yanwei Lu, Ye Zhao, Rui Meng, Sheng Zhang, Xiaorong Dong, Shuangbing Xu, and Gang Wu. Ube2o targets mxi1 for ubiquitination and degradation to promote lung cancer progression and radioresistance. Cell Death &amp; Differentiation, 28(2):671–684, September 2020. URL: http://dx.doi.org/10.1038/s41418-020-00616-8, doi:10.1038/s41418-020-00616-8. This article has 51 citations.](https://doi.org/10.1038/s41418-020-00616-8)

[9. (Lee1999Mxi1) Theodore C. Lee and Edward B. Ziff. Mxi1 is a repressor of the c-myc promoter and reverses activation by usf. Journal of Biological Chemistry, 274(2):595–606, January 1999. URL: http://dx.doi.org/10.1074/jbc.274.2.595, doi:10.1074/jbc.274.2.595. This article has 56 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.274.2.595)

[10. (Lei2022Mxi1) Yujie Lei, Yunchao Huang, Jianbin Lin, Shihui Sun, Keda Che, Junting Shen, Jun Liao, Yangming Chen, Kai Chen, Zhaoxian Lin, and Xing Lin. Mxi1 participates in the progression of lung cancer via the microrna-300/klf9/gadd34 axis. Cell Death &amp; Disease, May 2022. URL: http://dx.doi.org/10.1038/s41419-022-04778-w, doi:10.1038/s41419-022-04778-w. This article has 7 citations.](https://doi.org/10.1038/s41419-022-04778-w)

[11. (Huang2018S6K1) Yumei Huang, Kaishun Hu, Sheng Zhang, Xiaorong Dong, Zhongyuan Yin, Rui Meng, Yingchao Zhao, Xiaofang Dai, Tao Zhang, Kunyu Yang, Li Liu, Kai Huang, Shaojun Shi, Yu Zhang, Junjie Chen, Gang Wu, and Shuangbing Xu. S6k1 phosphorylation-dependent degradation of mxi1 by β-trcp ubiquitin ligase promotes myc activation and radioresistance in lung cancer. Theranostics, 8(5):1286–1300, 2018. URL: http://dx.doi.org/10.7150/thno.22552, doi:10.7150/thno.22552. This article has 27 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7150/thno.22552)

[12. (Cascón2012MAX) Alberto Cascón and Mercedes Robledo. Max and myc: a heritable breakup. Cancer Research, 72(13):3119–3124, July 2012. URL: http://dx.doi.org/10.1158/0008-5472.can-11-3891, doi:10.1158/0008-5472.can-11-3891. This article has 132 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-11-3891)

[13. (Tsao2008Inhibition) Chun Chui Tsao, Bin T. Teh, Eric Jonasch, Nicole Shreiber-Agus, Eleni Efstathiou, Anh Hoang, P. Bogdan Czerniak, Christopher Logothetis, and Paul G. Corn. Inhibition of mxi1 suppresses hif-2α-dependent renal cancer tumorigenesis. Cancer Biology &amp; Therapy, 7(10):1619–1627, October 2008. URL: http://dx.doi.org/10.4161/cbt.7.10.6583, doi:10.4161/cbt.7.10.6583. This article has 14 citations.](https://doi.org/10.4161/cbt.7.10.6583)